362 related articles for article (PubMed ID: 30042074)
1. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.
Gangi A; Shah J; Hatfield N; Smith J; Sweeney J; Choi J; El-Haddad G; Biebel B; Parikh N; Arslan B; Hoffe SE; Frakes JM; Springett GM; Anaya DA; Malafa M; Chen DT; Chen Y; Kim RD; Shridhar R; Kis B
J Vasc Interv Radiol; 2018 Aug; 29(8):1101-1108. PubMed ID: 30042074
[TBL] [Abstract][Full Text] [Related]
2. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
[TBL] [Abstract][Full Text] [Related]
3. Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis.
Buettner S; Braat AJAT; Margonis GA; Brown DB; Taylor KB; Borgmann AJ; Kappadath SC; Mahvash A; IJzermans JNM; Weiss MJ; Lamarca A; Bell JK; Valle JW; Hagendoorn J; Koerkamp BG; Sze DY; Lam MGEH
J Vasc Interv Radiol; 2020 Jul; 31(7):1035-1043.e2. PubMed ID: 32473757
[TBL] [Abstract][Full Text] [Related]
4. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis.
Mouli S; Memon K; Baker T; Benson AB; Mulcahy MF; Gupta R; Ryu RK; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2013 Aug; 24(8):1227-34. PubMed ID: 23602420
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma.
Malone CD; Gibby W; Tsai R; Kim SK; Lancia S; Akinwande O; Ramaswamy RS
J Vasc Interv Radiol; 2020 May; 31(5):701-709. PubMed ID: 32127318
[TBL] [Abstract][Full Text] [Related]
6. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
[TBL] [Abstract][Full Text] [Related]
7. Yttrium-90 Transarterial Radioembolization for Chemotherapy-Refractory Intrahepatic Cholangiocarcinoma: A Prospective, Observational Study.
White J; Carolan-Rees G; Dale M; Patrick HE; See TC; Bell JK; Manas DM; Crellin A; Slevin NJ; Sharma RA
J Vasc Interv Radiol; 2019 Aug; 30(8):1185-1192. PubMed ID: 31255499
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
[TBL] [Abstract][Full Text] [Related]
9. Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma.
Mosconi C; Cappelli A; Ascanio S; Pettinari I; Modestino F; Renzulli M; Galaverni MC; Cucchetti A; Gramenzi A; Pettinato C; Golfieri R
Future Oncol; 2017 Jun; 13(15):1301-1310. PubMed ID: 28343412
[TBL] [Abstract][Full Text] [Related]
10. Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma-A Prospective Feasibility Study.
Kis B; Shridhar R; Mhaskar R; Gyano M; Frakes JM; El-Haddad G; Choi J; Kim RD; Hoffe SE
J Vasc Interv Radiol; 2023 Sep; 34(9):1547-1555. PubMed ID: 37210030
[TBL] [Abstract][Full Text] [Related]
11. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study.
Ibrahim SM; Mulcahy MF; Lewandowski RJ; Sato KT; Ryu RK; Masterson EJ; Newman SB; Benson A; Omary RA; Salem R
Cancer; 2008 Oct; 113(8):2119-28. PubMed ID: 18759346
[TBL] [Abstract][Full Text] [Related]
12. Yttrium-90 Radioembolization Is Cost Effective in Intrahepatic Cholangiocarcinoma: A SEER Medicare Population Study.
Ghodadra A; Xing M; Zhang D; Kim HS
J Vasc Interv Radiol; 2019 Mar; 30(3):293-297. PubMed ID: 30819468
[TBL] [Abstract][Full Text] [Related]
13. Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results.
Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
J Cancer Res Clin Oncol; 2017 Mar; 143(3):481-489. PubMed ID: 27826686
[TBL] [Abstract][Full Text] [Related]
14. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Survival after Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases.
Weiner AA; Gui B; Newman NB; Nosher JL; Yousseff F; Lu SE; Foltz GM; Carpizo D; Lowenthal J; Zuckerman DA; Benson B; Olsen JR; Jabbour SK; Parikh PJ
J Vasc Interv Radiol; 2018 Aug; 29(8):1094-1100. PubMed ID: 29754852
[TBL] [Abstract][Full Text] [Related]
16. Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-Institution Retrospective Study.
Kayaleh R; Krzyston H; Rishi A; Naziri J; Frakes J; Choi J; El-Haddad G; Parikh N; Sweeney J; Kis B
J Vasc Interv Radiol; 2020 Jul; 31(7):1060-1068. PubMed ID: 32534978
[TBL] [Abstract][Full Text] [Related]
17. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option.
Saxena A; Bester L; Chua TC; Chu FC; Morris DL
Ann Surg Oncol; 2010 Feb; 17(2):484-91. PubMed ID: 19876691
[TBL] [Abstract][Full Text] [Related]
18. Survival and Toxicities after Yttrium-90 Transarterial Radioembolization of Cholangiocarcinoma in the RESiN Registry.
Robinson TJ; Du L; Matsuoka L; Sze DY; Kennedy AS; Gandhi RT; Kouri BE; Collins ZS; Kokabi N; Grilli CJ; Wang EA; Lee JS; Brown DB
J Vasc Interv Radiol; 2023 Apr; 34(4):694-701.e3. PubMed ID: 36509236
[TBL] [Abstract][Full Text] [Related]
19. Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma.
Kis B; Shah J; Choi J; El-Haddad G; Sweeney J; Biebel B; Mellon E; Frakes JM; Hoffe SE; Fishman MN; Shridhar R
J Vasc Interv Radiol; 2017 Feb; 28(2):254-259. PubMed ID: 27955832
[TBL] [Abstract][Full Text] [Related]
20. Yttrium-90 Radioembolization of Advanced, Unresectable Breast Cancer Liver Metastases-A Single-Center Experience.
Pieper CC; Meyer C; Wilhelm KE; Block W; Nadal J; Ahmadzadehfar H; Willinek WA; Schild HH
J Vasc Interv Radiol; 2016 Sep; 27(9):1305-1315. PubMed ID: 27461588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
